5Sitbon O,Humbert M,Jais X,et al.Long-term response to calcium channel blockers in idiopathie pulmonary arterial hypertension[J].Circalation,2005,111(23):3105-3111.
6McLaughlin VV,Shillington A,Rich S.Survival in primary pulmonary hypertension:the impact of epoprostenol therapy[J].Circulation,2002,106(12):1477-1482.
7Barst RJ.Recent advances in the treatment of pediatric pulmonary artery hypertension[J].Pediatr Clin North Am,1999,46(2):331-345.
8Barst RJ,Rubin LJ,Long WA,et al.A comparison of continuous intravenous epoprostenol(prostacyclin)with conventional therapy for primary pulmonary hypertension[J].N Engl J Med,1996,334(5):296-301.
9Simonneau G,Barst RJ,Galie N,et al.Continuous subcutaneous infusion of treprostinil,a pmstacyclin analogue,inpatients with pulmonary arterial hypertension:a double-blind,randomized,placebo controlled trial[J].Am J Respir Crit Care Med,2002,165(6):800-804.
10Tapson VF,Gomberg-Maitland M,McLaughlin,et al.Safety and efficacy of IV treprostinil for pulmonary arterial hypertension:a prospective,multicenter,open-label,12-week trial[J].Chest,2006,129(3):683-688.
